OLP is a rare phenomenon in pediatric patients, and only a few cases have been reported in the literature to date [4]. The prevalence of pediatric OLP varies from 0.03 to 0.56%, compared with approximately 2.2% of the general population [1, 5, 6, 9]. Cascone et al. reviewed 26 pediatric OLP cases between 1966 and 2015 and described that the average onset age was 10.41 ± 3.24 years [4]. The case reported here was diagnosed with OLP at only 3 years of age, the youngest case documented to date.
OLP manifests variability in clinical presentation, ranging from a classic lace-like network of slightly raised white lines with multifocal symmetrical distribution to erythematous and painful erosive lesions. Many studies have suggested that oral lesions of pediatric patients have the classic clinical presentation of OLP [4, 10, 11]. Similar to adults, asymptomatic reticulation is the dominant form of pediatric OLP [4]. Besides, the buccal mucosa is the most common site affected by OLP in pediatric patients [11]. In our case, the pediatric patient presented multifocal, symmetrical reticular and papular lesions accompanied by scattered erosions, suggesting a provisional diagnosis of OLP, which was confirmed by histopathological findings.
Although lichen planus is usually a sporadic disease, a familial form has been reported in 1 to 4.3% of pediatric patients. Studies have shown that the most notable features of familial OLP include early age of onset, widespread presentation on the oral mucosa, frequent clinical relapses, and increased disease severity [7, 12, 13]. Increasing evidence has found linkage of familial series with human leukocyte antigen (HLA) genes, such as HLA-B7, HLA-BR10, and HLA-D [8, 12, 14]. Currently, only two case reports are available on OLP’s inheritance in first-degree relatives among the pediatric population. One described a 12-year-old girl with whitish streaks on the oral mucosa, whose mother also exhibited whitish streaks on the buccal mucosa and violaceous patches on the tongue [7]. The other reported that an 11-year-old boy was affected by an erythematous lesion with a violaceous hue on the right half of the tongue, his father and grandmother both had oral involvement confirmed as OLP [8]. However, in our case, the condition was diagnosed at 3 years of age, and the clinical presentation was more complex and varied. The patient’s oral lesions affected the lips, the tongue, and the buccal mucosa, which were multifocal and have rarely been reported. Additionally, the boy’s parents were clinically and histopathologically diagnosed as affected by OLP, which has not been reported in the familial form before.
According to an updated review about OLP treatment, the aims of therapeutic management are eliminating painful symptoms, promoting healing of erosive lesions, reducing the risk of malignant transformation, and prolongating symptom free periods [15]. For erosive OLP, corticosteroids were recommended as first-line treatment in consensus guidelines [15, 16]. However, systemic or topical application of corticosteroids present various adverse effects, containing oral candidiasis, a smarting sensation in the mouth, gingival tenderness, insomnia, mood swings, fatigue, and water retention [16,17,18]. Moreover, there is no definitive protocol of corticosteroid therapy for children aged three. Here, we tried to treat the child with safer drugs to avoid corticosteroids’ adverse effects. bFGF is a pleiotropic cytokine that promotes angiogenesis and neurotrophy, and is important in the maintenance of mucosal integrity [19]. Pharmacological studies have shown that rb-bFGF stimulates mRNA, DNA, and protein synthesis in fibroblasts and endothelial cells [20]. Besides, rb-bFGF promotes keratinocyte division, epidermal regeneration, and granulation tissue formation, thus repairing tissue damage and accelerating wound healing [20]. Moreover, in clinical practice, we have used rb-bFGF gel to treat ulcerative and erosive lesions effectively. Li et al. also reported that topical application of rb-bFGF had positive effects over ulceration healing for a six-year old patient [21]. Therefore, in this case, the boy underwent rb-bFGF gel instead of corticosteroids. Fortunately, the patient’s oral erosions healed gradually, without adverse effects.
OLP is one of OPMDs according to the WHO criteria, with a malignancy potential rate of 0.4 to 12.5% [1]. Our previous study reported four cases with malignant transformation, which occurred at sites previously diagnosed by clinical examination as erosive or atrophic OLP [5]. Thus, continued clinical follow-ups are essential for monitoring OLP’s malignant transformation, especially when there are erosive and atrophic lesions. Alrashdan et al. recommended that regular follow-up ranging from every 2 months to once a year might be accepted in the long-term care for OLP patients [2]. Malignancy risk in children has rarely been reported, however, it is still necessary to consider the possibility of malignant transformation in pediatric OLP. Therefore, we suggest that pediatric populations in OLP also need regular annual follow-ups. In this case, the boy and his parents had good prognosis and their lesions had almost faded over 8 years.
In summary, we reported a case of a 3-year-old boy affected by OLP and with familial aggregation, whose lesions faded spontaneously during an 8-year follow-up. OLP lesions are recalcitrant and pre-malignant, particularly when erosive or atrophic lesions are present. Therefore, regular annual follow-ups are recommended in pediatric patients with OLP to monitor any changes in oral lesions.
